Advertisement
Screener

TriSalus Life Sciences, Inc. (TLSI) Graph

TLSI Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2020-09-30: Net income (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TLSI revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$11.41MCost of revenue$1.51MGross profit$9.90MOperating income-$9.81MOther income, net$90.00KResearch & development$3.14MPre-tax income-$9.18MIncome tax$4.00KNet income-$9.19M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endNet income
2020-09-30(m)

Revenue and expense 2 month

Period endNet income
2021-03-31-$372.03K

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2026-06-30$11.41M$1.51M$3.14M$4.00K-$9.19M
2026-03-31$8.90M$1.23M$3.22M$4.00K$1.54M
2025-12-31$13.21M*$1.76M*$2.57M*$0.00*-$9.75M*
2025-09-30$11.57M$1.91M$5.18M$5.00K-$10.81M
2025-06-30$11.21M$1.80M$3.67M-$3.00K-$8.29M
2025-03-31$9.17M$1.50M$3.02M$5.00K-$10.38M
2024-09-30$7.35M$1.00M$4.22M-$3.00K-$2.40M
2024-06-30$7.36M$912.00K$4.67M$7.00K-$4.33M
2024-03-31$6.46M$971.00K$5.84M$3.00K-$13.21M
2023-09-30$5.19M$589.00K$9.51M$0.00-$1.43M
2023-06-30$4.61M$772.00K$6.89M$13.00K-$13.98M
2023-03-31$2.98M$662.00K$5.64M-$5.00K-$8.31M
2022-09-30$3.92M$701.00K$4.81M$0.00-$8.09M
2022-06-30(m)(m)(m)$28.20K-$8.68M
2022-03-31(m)(m)(m)$0.00-$7.87M
2021-09-30(m)(m)(m)$0.00$1.86M
2021-06-30(m)(m)(m)$0.00$378.87K
2021-03-31(m)(m)(m)$0.00-$372.03K

Revenue and expense 4 month

Period endIncome taxNet income
2020-12-31$0.00-$711.39K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2026-06-30$20.31M$2.74M$6.35M$8.00K-$7.65M
2025-06-30$20.38M$3.30M$6.69M$2.00K-$18.66M
2024-06-30$13.82M$1.88M$10.51M$10.00K-$17.54M
2023-06-30$7.60M$1.43M$12.50M$8.00K-$22.24M
2022-06-30(m)(m)(m)$28.20K$5.22M
2021-06-30(m)(m)(m)$0.00$6.83K

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-09-30$31.95M$5.20M$12.39M$7.00K-$29.47M
2024-09-30$21.17M$2.89M$14.73M$7.00K-$19.94M
2023-09-30$12.79M$2.02M$22.07M$8.00K-$23.72M
2022-09-30$9.17M$1.44M$15.09M$3.00K-$24.64M
2021-09-30(m)(m)(m)$0.00$1.87M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-12-31$45.15M$6.96M$14.96M$7.00K-$39.23M
2024-12-31$29.43M$4.10M$17.69M$6.00K-$30.05M
2023-12-31$18.51M$2.60M$29.84M$9.00K-$59.36M
2022-12-31$12.40M$2.26M$21.36M$9.00K-$47.19M
2021-12-31(m)(m)(m)$0.00$4.77M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cytosorbents Corp (CTSO)United States$0.274B-1.29
Mobia Medical, Inc. (MOBI)United States$0.293B
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
Embecta Corp. (EMBC)United States$0.319B2.10
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
PRO DEX INC (PDEX)United States$0.234B13.64
Neuronetics, Inc. (STIM)United States$0.216B-3.25